Israel's Teva Claims Sales Record for Copaxone MS Therapy

Israeli drugmaker Teva has claimed that its global sales of Copaxone, an ethical injectable therapy for muscular degenerative disorder multiple schlerosis, reached record levels of US$261mn in the fourth quarter of 2004. The results bring the drug's full-year sales to US$936mn, or about 30% higher than in 2003. Company sources now claim that the therapy is rapidly becoming the market leader in the US, which accounts for about 58% of the drug's global sales.